AI Algorithm Listens To Patients Pass Urine for Assessing Urinary Tract Symptoms
|
By LabMedica International staff writers Posted on 05 Jul 2022 |

Lower urinary tract symptoms, problems related to the working of the bladder and the urethra, are common and affect an estimated 60% of men and 57% of women. Uroflowmetry is an important tool for the assessment of patients with symptoms, but patients have to urinate into a machine during outpatient visits. They are asked to urinate into a funnel connected to the uroflowmeter which records information about flow. During the COVID-19 pandemic access to clinics has been restricted, and even where patients can attend, the test can take a long time with queues to use a single machine. Now, an artificial intelligence (AI) algorithm trained to listen to patients pass urine can identify abnormal flows and could be a useful and cost-effective means of monitoring and managing urology patients at home.
The deep learning tool, Audioflow, that was developed by researchers at the Singapore General Hospital (Singapore) performed almost as well as a specialist machine used in clinics, and achieved similar results to urology residents in assessing urinary flow. The current study focused on sound created by urine in a soundproof environment, but the ambition is to create an app so patients can monitor themselves at home. In order to train and validate the algorithm, the researchers recruited 534 male participants between December 2017 and July 2019 to it. Participants used the usual uroflowmetry machine in a soundproofed room, and recorded their urination using a smartphone.
Using 220 recordings, the AI learned to estimate flow rate, volume, and time which can indicate when there is an obstruction or if the bladder is not working well. It was trained to listen to and analyze male urinary flow which is different from that of women and would need a separate sample to learn to analyze female urination. The results were compared to a conventional uroflowmetry machine and to a panel of six urology residents who separately graded the dataset. The AI agreed with conventional uroflowmetry for over 80% of recordings, and compared to the specialist urologists and external residents for identification of abnormal flows, it achieved an 84% rate of agreement. Audioflow will now be rolled out as a smartphone app via primary care physicians so it can be tested in the real world and learn from different datasets in different noise environments.
“There is a trend towards using machine learning in many fields, because clinicians do not have a lot of time. At the same time, particularly since the pandemic there is a shift towards telemedicine and less hospital-based care. We were keen to develop a way to monitor our patients to see how they are doing between hospital visits,” said Dr. Lee Han Jie from the Singapore General Hospital who led the development of the algorithm. “Our AI can outperform some non-experts and comes close to senior consultants. But the real benefit is having the equivalent of a consultant in the bathroom with you, every time you go. We are now working towards the algorithm being able to work when there is background noise in the normal home environment and this will make the true difference for patients.”
“Giving patients the ability to measure urinary flow at home is more comfortable for them and reduces time waiting in the clinic,” said Christian Gratzke, Professor of Urology at University Hospital Freiburg and member of the EAU22 Scientific Congress Committee of Urology. “This is a well-executed study with a significant number of patients and represents a promising approach to developing a portable app that can be used at home. I look forward to seeing the real-world results.”
Related Links:
Singapore General Hospital
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







